The members of the task force on Methodology for the Development of Innovative Cancer Therapies.
Introduction
The New Drug Development Office (NDDO) Research Foundation established the 'Methodology for the Development of Innovative Cancer Therapies' (MDICT) task force in 2006 to provide guidance on the development of novel anticancer agents. The task force has published a number of recommendations [1] [2] [3] [4] . The 2018 meeting of the MDICT task force was held on 4
March 2018, in conjunction with the 18th International Symposium on Targeted Anticancer Therapies (ESMO-TAT) in Paris. Participants included experts from academia, non-profit, industry and regulatory stakeholders. The mandate of the meeting was to review current knowledge and make recommendations regarding the design and conduct of early clinical studies of immuno-oncology (IO) agent combinations. We report here on the meeting and the task force recommendations.
IO agents are an exciting new class of anticancer therapeutics. Agents targeting the Cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death protein ligand-1 (PD-L1) pathways are the most studied, and have received marketing approvals for a number of tumour types, including melanoma, lung, renal, bladder, Hodgkin's lymphoma (HL), head and neck cancers, and mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) solid tumours [5] [6] [7] [8] [9] [10] [11] . Unfortunately, only a fraction of unselected patients derive benefit from these agents and the magnitude of benefit depends on the disease. For example, single agent anti-PD-1 treatment in patients with relapsed or refractory HL shows response rates of 65%-70% (including 9%-22% complete responses) [9, 12] , whereas first-line treatment of advanced non-small-cell lung cancer (NSCLC) with anti-PD-1 requires either patient selection by PD-L1 biomarker [13] or combination with chemotherapy [14] . Responses can be deep and durable, and in some instances maintained off therapy, as demonstrated by the plateau in the survival curve reported in patients with melanoma treated with ipilimumab [15] . Many more new IO agents targeting other immune-related pathways are being actively investigated in pre-clinical studies and in the clinic [16] in an attempt to improve outcomes.
The field continues to face important challenges related to the evaluation of IO agents in early phase clinical trials. Tumour responses to IO agents can follow unusual patterns that may be inadequately captured by traditional end point measurement methods, such as response-based end points evaluated by RECIST 1.1, including median progression-free survival (PFS). There is a clear need to develop new or modified end points that reflect IO specific antitumour activity. Furthermore, a daunting task is how to rationally and efficiently combine IO agents in appropriately profiled patient groups.
Scientific review and discussion

Scientific review
The IO field has seen an unprecedented growth since the initial reports of clinical activity with checkpoint inhibitors targeting CTLA-4 and PD-(L)1 [5, 17, 18] . A recently published comprehensive landscape analysis highlighted the breadth of innovation as well as the challenges [16] . As of September 2017, there are an astounding 2004 new IO agents in development, of which over 900 are in the clinic, and modulating 271 different targets. Vaccines represent the largest class of agents (344), but cell therapies are growing the fastest, particularly in China. Clinical studies with IO agents combinations have substantially increased and 165 different targets are being combined with anti-PD-(L)1 agents.
The landscape analysis also identified significant duplication and inefficiencies. There are over 160 agents targeting anti-PD-(L)1, including 50 in the clinic, and 34 of which are monoclonal antibodies. Anti-PD-(L)1 agents are most commonly being combined with anti-CTLA-4 agents (251 trials), followed by chemotherapy (170 trials). Furthermore, the planned enrolment of anti-PD-(L)1 combination studies has decreased from 250 to 500 patients per study in the period of 2010-2013, to just over 100 per study in 2017. This reflects a growing trend towards smaller investigator-initiated trials, many of which attempt to answer similar questions and are often conducted at single centres. In the first nine months of 2017, there were over 400 new PD-1/L1 combination studies posted to clinicaltrials.gov with a total target enrolment of over 50 000 patients.
The MDICT then discussed the challenges in using traditional end points to capture the unique tumour kinetics observed with immunotherapy. Pseudoprogression describes a clinical scenario where progressive disease is declared on the basis of RECIST 1.1 (new target lesions, unequivocal progression driven by nontarget disease, or increase in the sum of measures of target lesions), but continued follow-up demonstrates stabilization or regression of these same lesions ( Figure 1A ). Recent analyses of pooled data from clinical trials suggests up to 8% and 14% of patients with NSCLC [19] and melanoma [20] , respectively, treated with anti-PD-1 agents beyond RECIST-defined progression had subsequent partial responses, although this occurs in less than 5% of all patients treated in these pooled analyses. The phenomenon of hyperprogression was also highlighted by several MDICT task force members. At least three different definitions have been proposed [21] [22] [23] , and all describe patients experiencing apparent rapid disease acceleration within a few weeks of initiating anti-PD-(L)1 therapy ( Figure 1A ). The frequency may differ by tumour type, with retrospective case series reporting hyperprogression in 9% of patients with melanoma [22] , 16% with NSCLC [24] , and up to 29% with head and neck squamous cell carcinoma [23] . Quantifying tumour growth kinetics before therapy initiation is critical to detect growth acceleration on therapy in order to understand whether this is a true phenomenon and its incidence. The task force discussed the need to adequately inform patients of this risk, if confirmed. However, a key limitation is that clinical trials databases typically only include baseline assessments of disease and do not capture data from previous imaging. Retrospective reviews are ongoing to better delineate the true incidence. Consideration should be given to including extra data collection in future clinical trials. Non-IO containing control groups would also help clarify the true incidence of hyperprogression with IO agents. Potential genomic biomarkers are being investigated, such as MDM2/MDM4 amplification and EGFR aberrations [21] .
The phenomena of pseudoprogression, hyperprogression, and prolonged disease control with IO agents have generated significant interest in using existing as well as developing alternative end points and measurement methods for clinical trials with IO agents. Time-dependent end points may better capture IO antitumour activity, such as landmark analyses of PFS or overall survival (OS) ( Figure 1B) , as has been previously suggested [25] . End points on the basis of tumour growth kinetics and quality of response are also actively being investigated [26] . Modifications to RECIST 1.1 for immune-based therapeutics, termed iRECIST were discussed [27] . Response and PFS defined by iRECIST should be used as a secondary end point for pivotal or registrational trials until validated. Although iRECIST was designed primarily to capture pseudoprogression ( Figure 1A) , it is recommended that clinical trials collect data before enrolment, as well as longer follow-up. These strategies should facilitate a better understanding of the true impact of these unusual response patterns on early clinical trial methodology. Collectively, these novel assessment methods and end points may help deconvolute the survival curves of IO agents, but also better inform go/no-go decisions for later stage drug development.
Next, the importance of biomarkers for IO combination development and trial design was discussed. A number of tumour baseline biomarkers have been associated with favourable outcomes to anti-PD-(L)1 therapy, such as PD-L1 expression, tumour infiltrating lymphocytes [28] , tumour mutation burden [29] [30] [31] , inflammatory signatures [32] , or mismatch repair deficiency [11] . There is also strong interest in understanding what baseline host factors may be relevant, such as the microbiome [33] , LDH, or relative eosinophil or lymphocyte counts [34] . However, these biomarkers have predominantly prognostic rather than predictive value, and relatively poor sensitivity and/or specificity. This may help enrich for certain subpopulations for clinical trials but limits their value at the individual patient level. In particular, there is an urgent need to understand the pharmacodynamic effects of different IO agents on immune cells and the tumour microenvironment. For example, increased expression of T-cell effector function markers such as granzyme B [28] or gene expression profiling [35] in tumour biopsies after the start of an anti-PD-(L)1 therapy strongly associated with response. On the other hand, high serum levels of the decoy receptor for IL-2, soluble CD25 (sCD25), after an initial dose of ipilimumab is associated with lack of response and poor prognosis [36] . On-treatment biomarker assessment may help design rational IO combinations with a pre-emptive strategy, where a second agent is added to a backbone IO agent based on a given biomarker. Different intervention time-points could be considered, e.g. to convert a best response of stable disease to a partial or even complete response.
Seamless design trials have attracted significant attention due to efficiencies and accelerated approval in the face of compelling data. A seamless design combines traditional phases into a single protocol, with later phases triggered by interim analyses of early phases. Merck's development of the anti-PD-1 agent pembrolizumab involved rapid addition of expansion cohorts after detecting clinical activity in early testing in KEYNOTE-001 (ClinicalTrials.gov number, NCT01295827). Accelerated approval for pembrolizumab in melanoma was obtained within 3 years of initiating the first-in-man study. Today, there are over 40 investigational new drug applications following the seamless design strategy [37] . However, there are a number of issues to consider for these studies. These trials can be quite complex with multiple amendments, which requires frequent communication between investigators and sponsors to ensure safety. Additionally, there are often many participating centres, which dilute the clinical experience and perhaps the identification of unique toxicities. Specific objectives, end points, and statistical analysis plans are often lacking. Members of the Clinical Trials Design task force of the Investigational Drug Steering Committee of the National Cancer Institute have drafted, and are planning to publish, recommendations addressing seamless designs. 
Discussion
Following the scientific review, the MDICT task force engaged in a discussion and focused on four questions outlined in the following.
What are the relevant data required to justify a combination immunotherapy clinical trial? Considering the landscape analysis identified over 900 IO agents in the clinic modulating 271 different targets, there are innumerable possible combinations and a rational approach is necessary. Concerns were raised that agents with little or no clinical activity are being combined with established checkpoint inhibitors, or even another inactive agent, as a 'salvage strategy' without a sound rationale, other than perhaps commercial interest and availability within a portfolio. The MDICT task force felt strongly that science should drive combinations, and not the converse. The MDICT task force stressed the necessity for a robust hypothesis, ideally backed by adequate pre-clinical evidence of additive or synergistic effects of the combination. Relevant pharmacodynamic markers should be established in pre-clinical models, which can then be evaluated in early phase clinical trials. However, the immunological context of pre-clinical models should be considered and whether it is translatable into man. For example, a systematic testing of host factors such as age, microbiota, and obesity in pre-clinical models has been suggested for immunotherapy agents, and is reviewed elsewhere [38] . The lack of adequate preclinical models was highlighted in the discussion, and while the development of humanized mouse xenograft models may help this is clearly an area where further work is required [39] . Ultimately, translation may be questionable, and pharmacodynamic studies in man as well as innovative trial designs may be necessary.
Optimal end points and designs for combination immunotherapy clinical trials. The discussion of optimal end points centred on the unique tumour kinetics observed with immunotherapy. Differentiating between pseudoprogression and true progression is challenging, with the associated risk of either discontinuing an effective drug or continuing an ineffective drug, respectively. The MDICT task force noted that pseudoprogression is usually considered in a patient that is symptomatically stable, or less commonly, improving. However, some patients may have a transient worsening of symptoms, especially if pseudoprogression occurs in areas that are critical (e.g. brain). Time-dependent end points, such as landmark analyses of PFS or OS at 1 or 2 years (as opposed to the median), may be more sensitive end points for IO agents. This also highlighted the necessity of pooling large datasets to identify optimal end points. OS is a gold standard end point but may lack sensitivity as more salvage therapies become available.
The need for randomization remains critical in later phase studies (phases II and III) with combinations, especially when one of the agents has clinical activity. The use of contemporaneous historical data has also been considered, but this does not generally replace prospective randomization.
The evaluation of pharmacodynamic biomarkers is critical in early phase combination trials and should be incorporated into trial objectives and go/no-go decisions. On-treatment biopsies should be considered in expansion cohorts once the RP2D has been established, before expanding to larger trials. Emerging technologies, such as multiplexed immunohistochemistry, can maximize data acquisition from often limited tissue, but can also help deconvolute the spatial complexity of the tumour microenvironment. There was a call to identify the relevant pharmacodynamic biomarkers to interrogate in biopsies. Evaluation of pharmacodynamic biomarkers is critical in early phase combination trials and should be incorporated into trial objectives and go/no-go decisions Trial designs:
• Master protocols (basket, umbrella, and platform designs) can significantly enhance efficiencies in evaluating multiple IO combination • Sequencing designs based on a pre-emptive strategy could be considered Efficacy end points should remain response based, with definitions for response, pseudoprogression, and hyperprogression. iRECIST should be used as secondary or exploratory end point Blood based biomarkers should be prospectively evaluated Hyperprogression: a real entity?
Protocols should capture at least one additional tumour measurement before baseline to determine tumour growth kinetics, and consider an early CT scan (at 4 weeks for example)
How to optimize efficiency and minimize redundancy?
Well-conceived master protocols are strongly encouraged Not re-testing a failed combination of in-class agents unless there is a compelling rationale Proposals of IO combinations should also have a landscape analysis to prevent duplication
Hyperprogression. Hyperprogression elicited strong opinions during the discussion. Some members of the MDICT task force questioned if hyperprogression is a real entity, while others wondered if it may in fact be pseudoprogression in some patients. It was felt that hyperprogression is more common with IO than chemotherapy, though data are lacking to support this. All agreed that this issue requires further study, and a common definition is needed to help define its incidence. The lack of access to previous imaging in current databases was identified as a major obstacle, but efforts to pool data from academic centres are underway. A systematic collection of patients' last imaging available before a clinical trial screening period would allow to calculate the tumour growth kinetics pre-/post-treatment and would help to characterize the impact of a novel therapy/regimen on the disease. The need for tissue sampling at the time of hyperprogression was emphasized in order to gain insights into possible mechanisms.
Optimizing efficiency and minimizing redundancy. The landscape analysis [16] provided a quantification of what was widely believed by all members of the MDICT task force: the IO field has unprecedented innovation, but also the potential for significant inefficiency and redundancy. It is highly questionable whether 251 clinical trials are necessary to evaluate the anti-PD-(L)1 and anti-CTLA-4 combination. Chemotherapy represented the second most common class of agents to be combined with anti-PD-(L)1 agents, and many of these 170 trials are evaluating different chemotherapy regimens. This partially reflects disease-specific chemotherapy regimens and settings. It will be interesting to see if an optimal chemotherapy 'backbone' can be identified given the emerging evidence that chemotherapy agents are different in their ability to induce an immunogenic cell death [40, 41] . The increase in smaller investigator-initiated studies, many of which address similar questions and are run at single centres, raised concerns that enrolment and/or significant statistical sample sizes may not be achieved for many studies, leaving many important questions unanswered while being wasteful of precious resources.
MDICT task force recommendations
Based on the scientific review and discussion, the MDICT task force made a series of recommendations for the selection, design and conduct of early phase clinical studies of immunotherapy agent (Table 1) .
Minimum data requirements to justify a combination immunotherapy clinical trial
A key idea underpinning the recommendations below is that science needs to drive IO combination development. To a large extent, the recommendations of the MDICT on combining targeted agents in 2013 [4] continue to be applicable.
1.
A robust hypothesis based on a good understanding of the biology of the targets. 2. Pre-clinical studies of the combination addressing:
a. Efficacy: There should be clear evidence of additive or synergistic effects of the combination in several relevant models of a given disease or subtype. If the translation into humans is questionable, it is essential to build pharmacodynamic assessments into early phase clinical trials to inform go/no-go decisions. b. Pharmacodynamics: the pharmacodynamic effects of individual agents and in combination should be understood to the extent possible given the limitations of pre-clinical models, so that they can be evaluated in human studies. c. Toxicology: pre-clinical combination toxicology studies have limited ability to predict human adverse events. 3. Evidence of single agent activity. If not available, there should be a compelling hypothesis and pre-clinical data to combine with other agents. 4. Combination immunotherapy trials rely on an adequate understanding of single agent dose and schedule. Unfortunately, there is a lack of precision on recommended dose and schedule, in part because toxicities and responses can be delayed. There is a critical need to develop an understanding of PK/PD relationships of single agents; data on receptor occupancy may help.
Optimal end points and designs for combination immunotherapy clinical trials
1. Clinical studies should have clear objectives with go/no-go criteria met before progressing to later phase studies.
Evaluation of pharmacodynamic biomarkers is critical in
early phase combination trials and should be incorporated into trial objectives and go/no-go decisions. Tissue sampling should be considered at different time-points, including for pre-defined pharmacodynamic end points, but also at the time of progression, unusual responses, and pseudo/hyperprogression. Tissue sampling is critical to investigate mechanisms of primary and adaptive resistance to IO agents. While a detailed discussion of appropriate biomarkers is beyond the scope of this review, a minimum biomarker analysis should include the quantification of the immune cell infiltrate and gene expression profiling, which may be specific to the class of agent, as well as the tumour mutational burden. Efforts to standardize IO pharmacodynamic biomarkers are encouraged, as has been done for the evaluation of tumourinfiltrating lymphocytes in breast cancer [42] . 3. Trial design. Randomization remains critical in later phase studies (phases II and III), especially when one of the agents has clinical activity. Historical controls are almost always inadequate, unless there is a strong rationale for the use of a well-defined contemporary cohort. Sequencing designs based on a pre-emptive strategy could be considered, but adequate biomarker evaluation is critical. Seamless designs are encouraged for agents with compelling antitumour activity with the urgency to get to patients. However, analytical plans should be stated a priori, and frequent and clear communication between the sponsor and investigators is essential. Finally, master protocols (basket, umbrella, and platform designs) can significantly enhance efficiencies in evaluating multiple IO combination, and have been discussed with the Food and Drug Administration (FDA) [43] . Several members of the MDICT are engaged in developing master protocols for IO combinations.
4. Patient selection. Small studies with biomarker end points could be carried out in earlier settings to increase precision in decision-making. For example, neo-adjuvant or window of opportunity studies could achieve more comprehensive immune profiling. All the relevant immune compartments could be evaluated, such as the tumour but also the invasive margin, tertiary lymphoid organs, draining lymph nodes, and blood. 5. Toxicity assessments should include the multiplicity of immune-related adverse events on a per patient basis and be reported separately. Hyperprogression should be reported, and the criteria used to identify hyperprogression should be clearly stated and justified, preferably based on a published definition [21] [22] [23] . While it is premature at this stage to recommend this, if hyperprogression is shown to be a possible outcome that may lead to shorter survival, it is feasible for future protocols to formally define hyperprogression-once a single definition is agreed on-as an adverse event to be reported. [45] . Clinical trials should report the response rate of the injected tumour, but also of the non-injected tumours to capture the abscopal effect. 8. Blood-based biomarkers should be prospectively evaluated in IO trials. Strategies based on ctDNA should be considered, but the dynamics of ctDNA on treatment need to be investigated. Early data from melanoma patients treated with adoptive transfer of activated autologous tumour-infiltrating lymphocytes suggest that early peaks of V600E ctDNA followed by clearing were strongly associated with complete responses [46] . Whether similar patterns exist with other IO agents remains to be investigated. Early on-treatment predictive biomarkers of clinical response could help in the design of clinical trials to evaluate duration of treatment with IO agents. If prospectively validated, a pre-emptive strategy sequencing trial could add a second IO agent in patients with high serum sCD25 after one dose of an anti-CTLA4 agent. A similar strategy based on a sustained increase in ctDNA could also be considered.
Hyperprogression
There is some disagreement on how to define hyperprogression, whether it truly exists as a paradoxical effect of immunotherapy, and how to differentiate it from pseudoprogression. There is insufficient data at present to make formal recommendations, but the following steps should be taken to answer these important questions.
1. Protocols should capture at least one additional tumour measurement before baseline to help determine tumour growth kinetics. A key issue is to ensure that clinical trial contracts do not preclude accessing or submitting imaging data before study entry. 2. Academic collaboration for pooling data from multiple clinical trials to help define the incidence, optimize a definition, and identify predictive factors. 3. Protocols should consider an early CT scan (at 4 weeks for example), which would not contribute to response assessment, but would help define the incidence of hyperprogression. As mentioned before, a biopsy should be considered at the time of hyperprogression to explore potential mechanisms. 4. As hyperprogression is better understood, the possible risks of hyperprogression should be included in patient informed consent.
Optimizing efficiency and minimizing redundancy 1. Optimizing efficiency. There are significant concerns that resources are not being used efficiently to answer the most important questions facing the field of immunotherapy. Seamless design trials increase speed, but may not increase efficiency without appropriate go/no-go criteria, especially for inactive drugs or combinations. It is vital to share data and results to minimize the number of identical but failed trials or analyses of irrelevant biomarkers. Well-conceived basket, umbrella, and platform clinical trial designs, collectively referred to as master protocols [43] , are strongly encouraged and are good opportunity to drive collaboration and efficiency. 2. Minimizing redundancy. The MDICT strongly recommended not re-testing a failed combination of in-class agents unless there is a compelling rationale and strong science to support. The review of proposals of IO combinations by funders, peer and institutional review boards, should also contain a landscape analysis, to minimize unnecessary duplication highimpact journals, such as the Journal of Clinical Oncology, are raising the bar and will not publish trials unless they add to the scientific body of knowledge. No further clinical trials testing the anti-PD-(L)1 and anti-CTLA-4 combination should be conducted, especially those which do not include pharmacodynamics biomarkers, unless a strong scientific rationale exists.
